Immunotherapy plus chemo may open door to surgery for inoperable lung cancer
NCT ID NCT07603661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the combination. After treatment, doctors will check if the tumor has shrunk enough for safe removal. The main goal is to see how many patients become eligible for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?